Clinical Trial

A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2303 in Healthy Adult

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
he goal this clinical trail is to evaluate the safety、Pharmacokinetic and immunogenicity of GR2303 injection。 Subjects will be enrolled in different groups in sequential order, and within each group will be randomly assigned to receive either GR2303 injection or placebo administration, with each Subjects will be enrolled in only one of these groups
Trial Details
NCT Number NCT07199270
Lead Sponsor Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Conditions Health Adult Subjects
Enrollment 64 participants
Start Date 2025-09-18
Primary Completion 2026-09-18 (estimated)
Study Completion 2026-12-16 (estimated)
Updated on ClinicalTrials.gov 2025-09-30